- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2016
- Public Summary Document (PSD) July 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2016 PBAC Meeting - Word
Ixekizumab – July 2016
Ixekizumab: 80 mg/mL injection 2 × 1 mL syringe, 80 mg/mL injection 2 x 1 mL injection device, Taltz®
Last updated
28 October 2016